

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

205,511

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/049970

INTERNATIONAL APPLICATION NO.  
PCT/JP00/05415INTERNATIONAL FILING DATE  
28 June 2000 (28.06.00)PRIORITY DATE CLAIMED  
12 August 1999 (12.08.99)

## TITLE OF INVENTION

ANTIBIOTIC CAPRAZAMYCINS AND PROCESS FOR PRODUCING THE SAME

APPLICANT(S) FOR DO/EO/US Tonio TAKEUCHI, Nasayuki IGARASHI, hiroshi NAGANAWA, Nasa HAMADA

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☒ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☒ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (unsigned)
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

## Items 11 to 20 below concern document(s) or information includ

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and
12. ☐ An assignment document for recording. A separate cover she
13. ☐ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordar
18. ☐ A second copy of the published international application und
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:  
International Application published under PCT (cover)

"EXPRESS MAIL" Label No.: ET537596505US

Date of Deposit: February 12, 2002

This correspondence is being  
Deposited with the United States  
Postal Service "Express Mail Post  
Office to Addressee" service under  
37 CFR § 1.10 on the date indicated  
above and addressed to:  
Commissioner of Patents and  
Trademarks, U.S. Patent and  
Trademark Office.  
Washington, D.C. 20231.

10/049970

J.S. APPLICATION NO. (if known) see 37 CFR 1.53

INTERNATIONAL APPLICATION NO

ATTORNEY'S DOCKET NUMBER

10/049970

PCT/JP00/05415

205,511

21. ☒ The following fees are submitted:

## CALCULATIONS PTO USE ONLY

**BASIC NATIONAL FEE (37 CFR 1.492 (a)(1)-(5)):**

Neither international preliminary examination fee (37 CFR 1.482)  
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO  
and International Search Report not prepared by the EPO or JPO ..... **\$1040.00**

International preliminary examination fee (37 CFR 1.482) not paid to  
USPTO but International Search Report prepared by the EPO or JPO ..... **\$890.00**

International preliminary examination fee (37 CFR 1.482) not paid to USPTO  
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... **\$740.00**

International preliminary examination fee (37 CFR 1.482) paid to USPTO  
but all claims did not satisfy provisions of PCT Article 33(I)-(4) ..... **\$710.00**

International preliminary examination fee (37 CFR 1.482) paid to USPTO  
and all claims satisfied provisions of PCT Article 33(I)-(4) ..... **\$100.00**

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

\$ 890.00

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$ 0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	11 - 20 =		x <b>\$18.00</b>	\$
Independent claims	4 - 3 =	1	x <b>\$84.00</b>	\$ 84.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ <b>\$280.00</b>	\$

**TOTAL OF ABOVE CALCULATIONS =**

\$ 974.00

☒ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above  
are reduced by 1/2. +

**SUBTOTAL =**

\$ 487.00

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(f)).

\$ 0.00

**TOTAL NATIONAL FEE =**

\$

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be  
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **\$40.00** per property +

\$ 0.00

**TOTAL FEES ENCLOSED =**

\$ 487.00

Amount to be  
refunded:

\$

charged:

\$

- a. ☒ A check in the amount of \$ 487.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any  
overpayment to Deposit Account No. 01-0035 A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card  
information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR  
1.137 (a) or (b)) must be filed and granted to restore the application to pending status.


SEND ALL CORRESPONDENCE TO

Thomas E. Spath

ABELMAN FRAYNE &amp; SCHWAB

150 East 42nd Street

New York, NY 10017-5612



SIGNATURE

Thomas E. Spath

NAME

25,928

REGISTRATION NUMBER

20/pvt  
1

# DESCRIPTION

## ANTIBIOTIC CAPRAZAMYCINS AND PROCESS FOR PRODUCING THE SAME

### Technical Field

5 This invention relates to new antibiotics, namely caprazamycins A, B, C, E and F or pharmaceutically acceptable salts thereof, which have excellent antibacterial activities. This invention also relates to a process for producing a caprazamycin. Further, this  
10 invention relates to a pharmaceutical composition, particularly an antibacterial composition, comprising a caprazamycin or a salt thereof as an active ingredient. Still further, this invention relates to Streptomyces sp. MK730-62F2, as a new microorganism, having a  
15 characteristic nature that it is capable of producing a caprazamycin.

### Background Art

In chemotherapy of bacterial infections, particularly chemotherapy of infections of acid-fast  
20 bacteria, there have hitherto been used rifampicin, kanamycin, streptomycin, viomycin, capreomycin, cycloserine and the like, as antibacterial drug.

A serious problem for the chemotherapy of the bacterial infections is in that bacteria causative for the  
25 bacterial infections become drug-resistant. In particular, the appearance of acid-fast bacteria which are resistant to rifampicin, kanamycin, streptomycin, viomycin, capreomycin, cycloserine and the like has brought about a

206050-0264001


social problem in respect of the chemotherapy of these bacterial infections. Thus, there is now a keen request for providing a novel chemotherapeutic agent which is effective against the bacterial infections as induced by the acid-fast bacteria resistant to antibacterial drug. Strongly requested also is a novel chemotherapeutic drug effective against the bacterial infections which are induced by atypical acid-fast bacteria and for which no chemotherapeutic treatment has been established yet. In order to meet these requisites, therefore, there exists a strong demand to find out or to create novel compounds which have novel chemical structure and can exhibit good properties such as excellent antibacterial activities in a different way from those of the known antibiotics as hitherto utilized. The object of this invention is therefore to provide novel antibiotics which have excellent antibacterial activities and are capable of meeting the requisites as above-mentioned.

#### Disclosure of the Invention

We, the inventors of this invention, have carried out our investigations with the intention of finding out useful antibiotics. As a result, we have now found that a new microbial strain which belongs to genus Streptomyce and has been isolated by us can produce plural antibiotics having a novel skeletal structure. We have now designated a class of these plural antibiotics, collectively, as a caprazamycin. We have further found that a caprazamycin exhibits strong antibacterial activities against a variety

of acid-fast bacteria and gram-positive bacteria as well as their drug-resistant strains. We have further proceeded our studies and have now found from the analysis of the caprazamycins, that the caprazamycins as now  
5 obtained by us include five compounds. We have designated these five compounds as caprazamycins A, B, C, E and F, respectively, and have decided their chemical structures. Furthermore, we have now found and confirmed that caprazamycins A, B, C, E and F are novel compounds and  
10 that they are collectively represented by a general formula (I) given below. By the way, these caprazamycins have a common and basic skeletal structure as shown in the general formula (I), wherein the side chain group R is a straight chain or branched chain alkyl group of 11 to 13  
15 carbon atoms different from each other.


According to a first aspect of this invention, therefore, there is provided an antibiotic, caprazamycin A, caprazamycin B, caprazamycin C, caprazamycin E or caprazamycin F, which is a compound represented by the  
20 following general formula (I)



wherein R is tridecyl group for caprazamycin A; 11-methyl-  
 dodecyl group for caprazamycin B; dodecyl group for  
 caprazamycin C; undecyl group for caprazamycin E; and 9-  
 methyl-decyl group for caprazamycin F, or a  
 pharmaceutically acceptable salt thereof.


The novel antibiotic, a caprazamycin as now provided  
 according to the first aspect of this invention includes  
 caprazamycin A of formula (Ia), caprazamycin B of formula  
 (Ib), caprazamycin C of formula (Ic), caprazamycin E of  
 formula (Ie) and caprazamycin F of formula (If) as shown  
 below.

(1) Caprazamycin A of the following formula (Ia)




[Compound of general formula (I) where R is tridecyl group  
 $-(CH_2)_{12}-CH_3$ ]


(2) Caprazamycin B of the following formula (Ib)



that is, compound of general formula (I) where R is 11-  
 methyl-dodecyl group




(3) Caprazamycin C of the following formula (Ic)



[Compound of general formula (I) where R is dodecyl group  $\text{---}(\text{CH}_2)_{11}\text{---CH}_3$  ].


(4) Caprazamycin E of the following formula (Ie)






[Compound of general formula (I) where R is undecyl group  $-(CH_2)_{10}-CH_3$ ], and

(5) Caprazamycin F of the following formula (If)



that is, a compound of general formula (I) where R is 9-methyl-decyl group




Physicochemical properties of caprazamycin A of formula (Ia) according to the first aspect of this invention are as follows.

(1) Appearance

25 Colorless powder

(2) Molecular formula



(3) High resolution mass spectrometry (HRFABMS: cation

mode)

Found: 1146.5933 (M+H)<sup>+</sup>

Calculated: 1146.5921

(4) Specific rotation

5         $[\alpha]_D^{23} -1.4^\circ$  (c 0.83, DMSO)

(5) Ultraviolet absorption spectrum (in methanol)

$\lambda_{\max}$  nm ( $\epsilon$ ): 261 (7,400)

The UV spectrum is shown in Figure 1 of attached drawings.

10    (6) Infrared absorption spectrum

As shown in Figure 2 of attached drawings.

(7) Proton nuclear magnetic resonance spectrum

Proton NMR spectrum as measured in DMSO-d<sub>6</sub> at 500 MHz at room temperature is shown in Figure 3 of attached drawings.

15    (8) <sup>13</sup>C-nuclear magnetic resonance spectrum

<sup>13</sup>C-NMR spectrum as measured in DMSO-d<sub>6</sub> at 125 MHz at room temperature is shown in Figure 4 of attached drawings.

(9) Solubility

20        Soluble in methanol, dimethylsulfoxide (DMSO) and water, but insoluble in acetone and ethyl acetate.

(10) TLC

When it is subjected to a thin layer chromatography on silica gel 60F<sub>254</sub> (a product of Merck & Co.) as developed with a solvent consisting of butanol-methanol-water (4:1:2), the R<sub>f</sub> value is 0.44.

25        Caprazamycin A according to the first aspect of this invention is an amphoteric substance, and the pharmaceuti-

206050-0464007


cally acceptable salts thereof may be exemplified by its salts with organic bases such as quaternary ammonium salts, its salts with various metals, for example, its salts with alkali metals such as sodium salt, or its acid addition salts with organic acids such as acetic acid or with inorganic acid such as hydrochloric acid.

Physicochemical properties of caprazamycin B of formula (Ib) according to the first aspect of this invention are as follows.

(1) Appearance

Colorless powder

(2) Molecular formula



(3) High resolution mass spectrometry (HRFABMS: anion mode)

Found: 1144.5750 (M-H)<sup>-</sup>

Calculated: 1144.5764

(4) Specific rotation

$[\alpha]_D^{23} -2.6^\circ$  (c 0.91, DMSO)

(5) Ultraviolet absorption spectrum (in methanol)

$\lambda_{\text{max}}$  nm ( $\epsilon$ ): 261 (8,000)

The UV spectrum is shown in Figure 5 of attached drawings.

(6) Infrared absorption spectrum

As shown in Figure 6 of attached drawings.

(7) Proton nuclear magnetic resonance spectrum

Proton NMR spectrum as measured in a solvent mixture of DMSO- $d_6$ -D<sub>2</sub>O (10:1) at 500 MHz at room temperature is

shown in Figure 7 of attached drawings.

(8)  $^{13}\text{C}$ -nuclear magnetic resonance spectrum

$^{13}\text{C}$ -NMR spectrum as measured in a solvent mixture of DMSO- $\text{d}_6$ - $\text{D}_2\text{O}$  (10:1) at 125 MHz at room temperature is shown  
5 in Figure 8 of attached drawings.

(9) Solubility

Soluble in methanol, DMSO and water, but insoluble in acetone and ethyl acetate.

(10) TLC

10 When it is subjected to a thin layer chromatography on silica gel 60F<sub>254</sub> (a product of Merck & Co.) as developed with a solvent consisting of butanol-methanol-water (4:1:2), the  $R_f$  value is 0.44.


Caprazamycin B according to the first aspect of this  
15 invention is an amphoteric substance, and the pharmaceutically acceptable salts thereof may be exemplified by its salts with organic bases such as quaternary ammonium salts, its salts with various metals, for example, its salts with alkali metals such as sodium salt, or its acid addition  
20 salts with organic acids such as acetic acid or with inorganic acid such as hydrochloric acid.

Physicochemical properties of caprazamycin C of formula (Ic) according to the first aspect of this invention are as follows.

25 (1) Appearance

Colorless powder

(2) Molecular formula



(3) High resolution mass spectrometry (HRFABMS: cation mode)

Found: 1132.5747 (M+H)<sup>+</sup>

Calculated: 1132.5764

5 (4) Specific rotation

$[\alpha]_D^{25} -1.1^\circ$  (c 1.33, DMSO)

(5) Ultraviolet absorption spectrum (in methanol)

$\lambda_{\text{max}}$  nm ( $\epsilon$ ): 261 (8,300)

The UV spectrum is shown in Figure 9 of attached  
10 drawings.

(6) Infrared absorption spectrum

As shown in Figure 10 of attached drawings.

(7) Proton nuclear magnetic resonance spectrum

Proton NMR spectrum as measured in DMSO-d<sub>6</sub> at 500 MHz  
15 at room temperature is shown in Figure 11 of attached  
drawings.

(8) <sup>13</sup>C-nuclear magnetic resonance spectrum

<sup>13</sup>C-NMR spectrum as measured in DMSO-d<sub>6</sub> at 125 MHz at  
room temperature is shown in Figure 12 of attached  
20 drawings.

(9) Solubility

Soluble in methanol, DMSO and water, but insoluble  
in acetone and ethyl acetate.

(10) TLC

25 When it is subjected to a thin layer chromatography  
on silica gel 60F<sub>254</sub> (a product of Merck & Co.) as  
developed with a solvent consisting of butanol-methanol-  
water (4:1:2), the R<sub>f</sub> value is 0.44.

Caprazamycin C according to the first aspect of this invention is an amphoteric substance, and the pharmaceutically acceptable salts thereof may be exemplified by its salts with organic bases such as quaternary ammonium salts, its salts with various metals, for example, its salts with alkali metals such as sodium salt, or its acid addition salts with organic acids such as acetic acid or with inorganic acid such as hydrochloric acid.

Physicochemical properties of caprazamycin E of formula (Ie) according to the first aspect of this invention are as follows.

(1) Appearance

Colorless powder

(2) Molecular formula

$C_{51}H_{83}N_5O_{22}$

(3) High resolution mass spectrometry (HRFABMS: cation mode)

Found: 1118.5613 (M+H)<sup>+</sup>

Calculated: 1118.5608

(4) Specific rotation

$[\alpha]_D^{25} -5.1^\circ$  (c 0.83, DMSO)

(5) Ultraviolet absorption spectrum (in methanol)

$\lambda_{max}$  nm ( $\epsilon$ ): 262 (7,700)

The UV spectrum is shown in Figure 13 of attached drawings.

(6) Infrared absorption spectrum

As shown in Figure 14 of attached drawings.

(7) Proton nuclear magnetic resonance spectrum

Proton NMR spectrum as measured in DMSO- $d_6$  at 500 MHz at room temperature is shown in Figure 15 of attached drawings.

(8)  $^{13}\text{C}$ -nuclear magnetic resonance spectrum

5  $^{13}\text{C}$ -NMR spectrum as measured in DMSO- $d_6$  at 125 MHz at room temperature is shown in Figure 16 of attached drawings.

(9) Solubility

Soluble in methanol, DMSO and water, but insoluble  
10 in acetone and ethyl acetate.

(10) TLC

When it is subjected to a thin layer chromatography on silica gel 60F<sub>254</sub> (a product of Merck & Co.) as developed with a solvent consisting of butanol-methanol-  
15 water (4:1:2), the  $R_f$  value is 0.44.


Caprazamycin E according to the first aspect of this invention is an amphoteric substance, and the pharmaceutically acceptable salts thereof may be exemplified by its salts with organic bases such as quaternary ammonium salts,  
20 its salts with various metals, for example, its salts with alkali metals such as sodium salt, or its acid addition salts with organic acids such as acetic acid or with inorganic acid such as hydrochloric acid.

Physicochemical properties of caprazamycin F of  
25 formula (If) according to the first aspect of this invention are as follows.

(1) Appearance

Colorless powder

## (2) Molecular formula



## (3) High resolution mass spectrometry (HRFABMS: cation mode)

5 Found: 1118.5615 (M+H)<sup>+</sup>

Calculated: 1118.5608

## (4) Specific rotation

$[\alpha]_{\text{D}}^{25} -4.7^\circ$  (c 0.90, DMSO)

## (5) Ultraviolet absorption spectrum (in methanol)

10  $\lambda_{\text{max}}$  nm ( $\epsilon$ ): 262 (7,600)

The UV spectrum is shown in Figure 17 of attached drawings.

## (6) Infrared absorption spectrum

As shown in Figure 18 of attached drawings.

## 15 (7) Proton nuclear magnetic resonance spectrum

Proton NMR spectrum as measured in DMSO- $\text{d}_6$  at 500 MHz at room temperature is shown in Figure 19 of attached drawings.

(8)  $^{13}\text{C}$ -nuclear magnetic resonance spectrum

20  $^{13}\text{C}$ -NMR spectrum as measured in DMSO- $\text{d}_6$  at 125 MHz at room temperature is shown in Figure 20 of attached drawings.

## (9) Solubility

Soluble in methanol, DMSO and water, but insoluble  
25 in acetone and ethyl acetate.

## (10) TLC

When it is subjected to a thin layer chromatography on silica gel 60F<sub>254</sub> (a product of Merck & Co.) as

206050-02664001



developed with a solvent consisting of butanol-methanol-water (4:1:2), the  $R_f$  value is 0.44.

Caprazamycin F according to the first aspect of this invention is an amphoteric substance, and the pharmaceuti-  
5 cally acceptable salts thereof may be exemplified by its salts with organic bases such as quaternary ammonium salts, its salts with various metals, for example, its salts with alkali metals such as sodium salt, or its acid addition salts with organic acids such as acetic acid or with  
10 inorganic acid such as hydrochloric acid.

By the way, the expression "a caprazamycin" simply given in this description may sometime mean either any one of caprazamycin A, caprazamycin B, caprazamycin C, caprazamycin E and caprazamycin F, or a mixture of two or  
15 more or a mixture of all of them.

Caprazamycins having the general formula (I) above according to this invention have biological properties hereinafter given.

Thus, caprazamycin A, caprazamycin B, caprazamycin C,  
20 caprazamycin E and caprazamycin F each exhibit antibacterial activities against such bacteria which embrace acid-fast bacteria, including their drug-resistant strains, as well as gram-positive bacteria, including their drug-resistant strains (methicillin-resistant  
25 strains, and others). The antibacterial activities of a caprazamycin against these bacteria are tested by the following procedures.

Test Example 1

The antibacterial spectrum of caprazamycin A against a variety of microorganisms were measured on a 1 % glycerin-supplemented nutrient agar medium by a serial  
5 dilution method according to the standard method as provided by Japanese Society of Chemotherapy. The test results are shown in Table 1.

10

15

20

25

2025070604004

Table 1

	Microorganisms tested	Caprazamycin A
		Minimum growth inhibitory concentration( $\mu\text{g/ml}$ )
5	<i>Mycobacterium smegmatis</i> ATCC607	1.56
	<i>Mycobacterium smegmatis</i> ATCC607 PM-R (paromomycin-resistant)	1.56
10	<i>Mycobacterium smegmatis</i> ATCC607 VM-R (viomycin-resistant)	0.78
	<i>Mycobacterium smegmatis</i> ATCC607 CPM-R (capreomycin-resistant)	0.78
15	<i>Mycobacterium smegmatis</i> ATCC607 ST-R (streptothricin-resistant)	0.78
	<i>Mycobacterium smegmatis</i> ATCC607 KM-R (kanamycin-resistant)	0.78
20	<i>Mycobacterium smegmatis</i> ATCC607 SM-R (streptomycin-resistant)	1.56
	<i>Mycobacterium smegmatis</i> ATCC607 RFP-R (rifampicin-resistant)	0.78
	<i>Mycobacterium phlei</i>	1.56
	<i>Mycobacterium vaccae</i> ATCC15483	0.2
25	<i>Mycobacterium fortuitum</i>	6.25

Test Example 2

The antibacterial spectrum of caprazamycin B against a variety of microorganisms were measured on a 1 %

glycerin-supplemented nutrient agar medium by a serial dilution method according to the standard method as provided by Japanese Society of Chemotherapy. The test results are shown in Table 2.

5 Table 2

	Microorganisms tested	Caprazamycin B
		Minimum growth inhibitory concentration ( $\mu\text{g/ml}$ )
	Mycobacterium smegmatis ATCC607	3.13
10	Mycobacterium smegmatis ATCC607 PM-R (paromomycin-resistant)	1.56
	Mycobacterium smegmatis ATCC607 VM-R (viomycin-resistant)	1.56
	Mycobacterium smegmatis ATCC607 CPM-R (capreomycin-resistant)	1.56
15	Mycobacterium smegmatis ATCC607 ST-R (streptothricin-resistant)	1.56
	Mycobacterium smegmatis ATCC607 KM-R (kanamycin-resistant)	1.56
	Mycobacterium smegmatis ATCC607 SM-R (streptomycin-resistant)	3.13
20	Mycobacterium smegmatis ATCC607 RFP-R (rifampicin-resistant)	3.13
	Mycobacterium phlei	3.13
	Mycobacterium vaccae ATCC15483	0.39
	Mycobacterium fortuitum	50

Test Example 3

25 The antibacterial spectrum of caprazamycin B against a variety of microorganisms other than the microorganisms as specified in Table 2 were measured on Müller-Hinton agar medium by a serial dilution method according to the

standard method as provided by Japanese Society of Chemotherapy. The test results are shown in Table 3.

Table 3

5	Microorganisms tested	Caprazamycin B
		Minimum growth inhibitory concentration ( $\mu\text{g/ml}$ )
	Staphylococcus aureus FDA209P	1.56
	Staphylococcus aureus Smith	3.13
	Staphylococcus aureus MS9610 (multiple drug-resistant)	3.13
10	Staphylococcus aureus No.5 (methicillin-resistant)	3.13
	Staphylococcus aureus No.17 (methicillin-resistant)	6.25
	Staphylococcus aureus MS16526 (methicillin-resistant)	3.13
15	Staphylococcus aureus TY-04282 (methicillin-resistant)	6.25
	Micrococcus luteus FDA16	3.13
	Micrococcus luteus PCI1001	3.13
	Bacillus anthracis	0.78
	Bacillus subtilis NRRL B-558	12.5
20	Bacillus subtilis PCI1219	6.25
	Bacillus cereus ATCC10702	3.13
	Corynebacterium bovis 1810	3.13
	Escherichia coli NIHJ	100

#### 25 Test Example 4

The antibacterial spectrum of caprazamycin C against a variety of microorganisms were measured on a 1 % glycerin-supplemented nutrient agar medium by a serial

dilution method according to the standard method as provided by Japanese Society of Chemotherapy. The test results are shown in Table 4.

Table 4

5	Microorganisms tested	Caprazamycin C
		Minimum growth inhibitory concentration ( $\mu\text{g/ml}$ )
	Mycobacterium smegmatis ATCC607	1.56
10	Mycobacterium smegmatis ATCC607 PM-R (paromomycin-resistant)	1.56
	Mycobacterium smegmatis ATCC607 VM-R (viomycin-resistant)	1.56
	Mycobacterium smegmatis ATCC607 CPM-R (capreomycin-resistant)	1.56
15	Mycobacterium smegmatis ATCC607 ST-R (streptothricin-resistant)	1.56
	Mycobacterium smegmatis ATCC607 KM-R (kanamycin-resistant)	0.78
	Mycobacterium smegmatis ATCC607 SM-R (streptomycin-resistant)	1.56
20	Mycobacterium smegmatis ATCC607 RFP-R (rifampicin-resistant)	1.56
	Mycobacterium phlei	1.56
	Mycobacterium vaccae ATCC15483	0.39
	Mycobacterium fortuitum	12.5

#### Test Example 5

The antibacterial spectrum of caprazamycin E against a variety of microorganisms were measured on a 1 % glycerin-supplemented nutrient agar medium by a serial dilution method according to the standard method as provided by Japanese Society of Chemotherapy. The test

results are shown in Table 5.

Table 5

5	Microorganisms tested	Caprazamycin E
		Minimum growth inhibitory concentration ( $\mu\text{g/ml}$ )
	Mycobacterium smegmatis ATCC607	1.56
	Mycobacterium smegmatis ATCC607 PM-R (paromomycin-resistant)	1.56
	Mycobacterium smegmatis ATCC607 VM-R (viomycin-resistant)	0.39
10	Mycobacterium smegmatis ATCC607 CPM-R (capreomycin-resistant)	0.39
	Mycobacterium smegmatis ATCC607 ST-R (streptothricin-resistant)	0.78
	Mycobacterium smegmatis ATCC607 KM-R (kanamycin-resistant)	0.78
15	Mycobacterium smegmatis ATCC607 SM-R (streptomycin-resistant)	1.56
	Mycobacterium smegmatis ATCC607 RFP-R (rifampicin-resistant)	0.78
	Mycobacterium phlei	1.56
	Mycobacterium vaccae ATCC15483	0.39
20	Mycobacterium fortuitum	12.5

Test Example 6

The antibacterial spectrum of caprazamycin F against a variety of microorganisms were measured on a 1 % glycerin-supplemented nutrient agar medium by a serial  
 25 dilution method according to the standard method as provided by Japanese Society of Chemotherapy. The test results are shown in Table 6.

Table 6

	Microorganisms tested	Caprazamycin F
		Minimum growth inhibitory concentration ( $\mu\text{g/ml}$ )
5	<i>Mycobacterium smegmatis</i> ATCC607	1.56
	<i>Mycobacterium smegmatis</i> ATCC607 PM-R (paromomycin-resistant)	0.78
	<i>Mycobacterium smegmatis</i> ATCC607 VM-R (viomycin-resistant)	1.56
10	<i>Mycobacterium smegmatis</i> ATCC607 CPM-R (capreomycin-resistant)	0.78
	<i>Mycobacterium smegmatis</i> ATCC607 ST-R (streptothricin-resistant)	0.78
	<i>Mycobacterium smegmatis</i> ATCC607 KM-R (kanamycin-resistant)	0.78
	<i>Mycobacterium smegmatis</i> ATCC607 SM-R (streptomycin-resistant)	1.56
15	<i>Mycobacterium smegmatis</i> ATCC607 RFP-R (rifampicin-resistant)	0.78
	<i>Mycobacterium phlei</i>	1.56
	<i>Mycobacterium vaccae</i> ATCC15483	0.78
	<i>Mycobacterium fortuitum</i>	12.5

20 Test Example 7

The antibacterial spectrum of each of caprazamycins A, B, C, E and F against Mycobacterium tuberculosis, and against atypical acid-fast bacteria, Mycobacterium avium kirchberg and Mycobacterium intracellulare, were measured

25 in a Middlebrook 7H9 liquid medium by a serial dilution method. At the same time, antibacterial spectra of rifampicin (RMP) and isonicotinic acid hydrazide (INH) (as comparative drug) against the above-mentioned acid-fast



bacteria were measured by the same serial dilution method. The results obtained are shown in the following Table 7.

Table 7

5	Compound tested	Minimum Inhibitory Concentration of Compound tested against Test Bacteria given below ( $\mu\text{g}/\text{mg}$ )		
		Mycobacterium tuberculosis H37Rv NIHJ-1633	Mycobacterium avium kirchberg NIHJ-1605	Mycobacterium intracellulare E-1 NIHJ-1618
10	Caprazamycin A	1.56	<0.025	0.78
	Caprazamycin B	1.56	<0.025	0.78
	Caprazamycin C	0.78	<0.025	0.78
	Caprazamycin E	0.78	<0.025	0.78
	Caprazamycin F	1.56	0.1	1.56
15	RMP(Comparative)	0.1	0.78	0.2
	INH(Comparative)	0.05	25	0.78

Further, according to a second aspect of this invention, there is provided a process for the production of antibiotics, caprazamycin A, caprazamycin B, caprazamycin C, caprazamycin E and/or caprazamycin F having the general formula (I) given above, characterized in that the process comprises culturing a microbial strain which belongs to the genus Streptomyces and which is capable of producing at least one of caprazamycin A, caprazamycin B, caprazamycin C, caprazamycin E and caprazamycin F, and recovering at least one of caprazamycins A, B, C, E and F from the resulting culture.

The microorganism or microbial strain, which is

capable of producing the antibiotic, a caprazamycin, and is usable in the process according to the second aspect of this invention, may be any strain of those microorganisms which have an ability of producing the said antibiotics that possess the above-mentioned physicochemical properties and biological properties, and it can be chosen from a wide variety of microorganisms. Among such usable microorganisms, there may be quoted a strain of actinomycetes, to which a strain number MK730-62F2 is allotted and which was isolated from a soil sample of Oafu island, Hawaii, by our Institute of Microbial Chemistry in March of 1997, as one preferred concrete example of the microorganism which is capable of producing the antibiotics, caprazamycins.

The microbiological properties of the strain MK730-62F2 are now described below.

#### 1. Morphology

The strain MK730-62F2 has branched substrate mycelia, from which extend relatively long aerial hyphae with the formation of 5- to 10-turned spirals at the tips of the aerial hyphae. Chain of the matured spores is in the form of a chain comprising 10 to 50 oval spores, and the dimensions of the spores are about 0.5 to 0.6 x 0.8 to 1.0 microns. The surface of the spores is smooth. Whirls, synnemata, sporangia and motile spores are not observed.

#### 2. Growth characteristics on various culture media

The standards of colors given in each of the brackets [ ] for the descriptions of colors are according

to "Color Harmony Manual" of Container Corporation of America.

(1) Sucrose-nitrate agar medium (cultured at 27°C)

Aerial hyphae of white in color are thinly formed on the growth of pale yellow [2 ea, Lt Wheat]. No soluble pigment is observed.

(2) Glycerol-asparagine agar medium (ISP-medium 5, cultured at 27°C)

Aerial hyphae of grayish white [3 dc, Natural] to light gray [d] are formed on the growth of pale yellow [2 ea, Lt Wheat] to pale yellowish brown [2 ng, Dull Gold]. No soluble pigment is observed.

(3) Inorganic salt-starch agar medium (ISP-medium 4, cultured at 27°C)

Aerial hyphae of white to light gray [d] are formed on the growth of pale yellow [2 ea, Lt Wheat] to pale yellowish brown [2 lg, Mustard Tan]. No soluble pigment is observed.

(4) Tyrosine agar medium (ISP-medium 7, cultured at 27°C)

Aerial hyphae of grayish white [b, Oyster White to 3 dc, Natural] are formed on the growth of pale yellowish brown [2 le, Mustard to 2 ng, Dull Gold], with the formation of dark brown soluble pigment.

(5) Yeast extract-malt extract agar medium (ISP-medium 2, cultured at 27°C)

Aerial hyphae of grayish white [b, Oyster White] to light gray [d] are formed on the growth of pale yellowish brown [2 ie, Lt Mustard Tan to 3 ic, Lt Amber].

20040301-02064001

No soluble pigment is observed.

(6) Oatmeal agar medium (ISP-medium 3, cultured at 27°C)

Aerial hyphae of grayish white [3 dc, Natural] to light gray [d] are formed on the growth of pale yellow [2 ea, Lt Wheat]. No soluble pigment is observed.

### 3. Physiological properties

(1) Temperature range for the growing

This strain MK730-62F2 was incubated in a glucose-asparagine agar medium (containing 1.0% glucose, 0.05% asparagine, 0.05% dipotassium hydrogen phosphate and 2.5% agar, at pH 7.0) at different temperatures of 10°C, 20°C, 24°C, 27°C, 30°C, 37°C, 45°C and 50°C each. The results showed that this strain could grow at the temperature range of 20°C to 37°C, excepting 10°C, 45°C and 50°C. The optimum temperature for growth is in the vicinity of 30 to 37°C.

(2) Hydrolysis of starch (in inorganic salts- starch agar medium, ISP-medium 4, cultured at 27°C)

The hydrolysis of starch was observed since about three days after the start of cultivation, and the degree of the hydrolytic activity is moderate.

(3) Formation of melanoid pigment (in Trypton-yeast extract broth, ISP-medium 1; peptone-yeast extract iron-agar medium, ISP-medium 6; tyrosine agar medium, ISP-medium 7; cultured at 27°C in each medium)

Positive in all the media used.

(4) Utilization of carbon sources (in Pridham-Gottlieb agar medium, ISP-medium 9, cultured at 27°C)

20040920 02064001

D-glucose, L-arabinose, D-fructose, sucrose, inositol, rhamnose, raffinose and D-mannitol are utilizable for the growth. D-xylose is probably utilizable.

- 5 (5) Reduction of nitrate (in aqueous peptone solution containing 0.1% potassium nitrate, ISP-medium 8, cultured at 27°C)

Negative.

- 10 (6) Liquefaction of gelatin (in gelatin medium, cultured at 20°C; and in glucose-peptone-gelatin medium, cultured at 27°C)

In the gelatin medium, no liquefaction was observed during 40 days after the start of cultivation; but in the glucose-peptone-gelatin medium, weak liquefaction was  
15 observed at about 40 days after the start of cultivation.

- (7) Coagulation and peptonization of skim milk (in 10% skim milk, cultured at 37°C)

No coagulation was observed. At about 7 days after the start of cultivation, initiation of peptonization was  
20 observed and the peptonization was completed at the 14th day from the start of cultivation.

Summarizing the above-mentioned properties of the strain MK730-62F2, this strain is characterized in that it has branched substrate mycelia, from which aerial hyphae  
25 are extended with formation of spirals; that the surface of spores is smooth; that on various culture media, aerial hyphae of grayish white to light gray in color are formed on the growth of pale yellow to pale yellowish brown in

color; that no soluble pigment is observed except the formation of melanoid pigment, that the optimum temperature for growth is in the vicinity of 30 to 37°C,; that the formation of melanoid pigment is positive; and  
 5 that the hydrolysis of starch is at a moderate degree. In addition, 2,6-diaminopimelic acid contained in the cell walls of this strain is of the LL-form, and the predominant menaquinone present in the bacterial cell is MK-9(H<sub>8</sub>) and MK-9(H<sub>6</sub>).

10 In view of these properties, it is presumed that the strain MK730-62F2 belongs to the genus Streptomyces. When searching for analogous known species with reference to the properties of this strain MK730-62F2, there have been found Streptomyces diastatochromogenes (Literature:  
 15 International Journal of Systematic Bacteriology, Vol.22, p.290, 1972), Streptomyces resistomycificus (Literature: International Journal of Systematic Bacteriology, Vol.18, p.165, 1968), Streptomyces collinus (Literature:  
 20 International Journal of Systematic Bacteriology, Vol.18, p.100 1968), and Streptomyces aurantiogriseus (Literature: International Journal of Systematic Bacteriology, Vol.18, p.297, 1968). Thus, we have actually examined the strain MK730-62F2 in comparison with the four strains as indicated above which were preserved in our Institute.  
 25 The results are shown in Table 8 below.

Table 8

5		Strain MK730-62F2	Streptomyces diastatochromo- genes IMC S-0712 (ISP 5449)	Streptomyces resistomyci- ficus IMC S-0212 (ISP 5133)
	Form of aerial hyphae	Spirals	Flexous to spirals	Spirals
	Surface of spores	Smooth	Smooth	Smooth
10	Color of aerial hyphae	Grayish white to light gray	Light gray	White to gray
	Color of growth	Pale yellow to pale yellowish brown	Pale yellow to Pale yellowish brown	pale yellowish brown to brownish brack
15	Soluble pigment	-	-	- to brown tinged
20	Formation of melanoid pigment in ISP 1 medium	(+)	+	+
	ISP 6 medium	+	+	+
	ISP 7 medium	(+)	+	(+)
	Reduction of nitrate	-	-	-
25	Hydrolysis of starch	+	+	+
	Coagulation of skim milk	-	-	-
	Peptonization of skim milk	+	(+)	-
	Liquefaction of gelatin	-	(+)	-

Table 8 (continued)

	Strain MK730-62F2	Streptomyces diastatochromo- -genes IMC S-0712 (ISP 5449)	Streptomyces resistomyci- ficus IMC S-0212 (ISP 5133)
5	Liquefaction of glucose-peptone- gelatin	(+)	(+)
	Utilization of carbon sources*		
10	L-arabinose	+	+
	D-xylose	(+)	(+)
	D-glucose	+	+
	D-fructose	+	+
	Sucrose	+	+
15	Inositol	+	+
	Rhamnose	+	+
	Raffinose	+	+
	D-mannitol	+	+

(Notes) \* + : Utilizable; (+) : Probably utilizable;  
 20 (±) : Doubtful, either utilizable or not utilizable.



Table 8 (continued)

5		Strain MK730-62F2	Streptomyces collinus IMC S-0201 (ISP 5129)	Streptomyces aurantiogri- seus IMC S-0069 (ISP 5138)
	Form of aerial hyphae	Spirals	Straight to loops	Spirals
	Surface of spores	Smooth	Smooth	Smooth
10	Color of aerial hyphae	Grayish white to light gray	White to grayish white	White to gray
	Color of growth	Pale yellow to pale yellowish brown	Pale yellowish brown to light brown	Pale yellowish brown to light brown
15	Soluble pigment	-	-	- to brown tinged
	Formation of melanoicl pigment in			
20	ISP 1 medium	(+)	(+)	+
	ISP 6 medium	+	+	+
	ISP 7 medium	(+)	(+)	(+)

Table 8 (continued)

		Strain MK730-62F2	Streptomyces collinus IMC S-0201 (ISP 5129)	Streptomyces aurantiogri- seus IMC S-0069 (ISP 5138)
5	Reduction of nitrate	-	-	+
	Hydrolysis of starch	+	+	+
	Coagulation of skim milk	-	-	-
10	Peptonization of skim milk	+	-	+
	Liquefaction of gelatin	-	-	(+)
	Liquefaction of glucose-peptone- gelatin	(+)	(+)	(+)
15	Utilization of carbon sources*			
	L-arabinose	+	+	+
	D-xylose	(+)	(+)	(+)
	D-glucose	+	+	+
	D-fructose	+	+	+
20	Sucrose	+	+	(+)
	Inositol	+	+	(+)
	Rhamnose	+	(+)	+
	Raffinose	+	+	+
	D-mannitol	+	+	+

(Notes) \* + : Utilizable; (+) : Probably utilizable;

25 (±) : Doubtful either utilizable or not utilizable.

As is clear from Table 8 above, the strain MK730-62F2 has properties which closely resemble to those of any of the strains which are compared therewith in Table 8.

However, Streptomyces resistomycificus is different from the strain MK730-62F2 in that, with Streptomyces resistomycificus, the color of the growth is pale yellowish brown to brownish black, the soluble pigment is tinged with brown, and skim milk is not peptonized. Streptomyces collinus is different from the strain MK730-62F2 in that, with the former species, the form of aerial hyphae is straight to loop, and skim milk is not peptonized. Streptomyces aurantiogriseus is distinguished from the strain MK730-62F2 in that, with the former species, the soluble pigment is tinged with brown, gelatin is liquefied and nitrate is reduced. On the other hand, Streptomyces diastatochromogenes resembles very closely to the strain MK730-62F2, except that the liquefaction of gelatin is positive with the former species. At this time, however, it is impossible that the strain MK730-62F2 is identified as one strain which belongs to Streptomyces diastatochromogenes. So, we have designated the strain MK730-62F2 as Streptomyces sp. MK730-62F2.

The strain MK730-62F2 has been deposited in a Japanese depository "National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology" located at No.1-3, Higashi 1-chome, Tsukuba-City, Ibaraki-ken, Japan, under the deposit number "FERM P-17067 on November 27, 1998. This strain has now been deposited under the deposit number "FERM BP-7218" in said National Institute as transferred in terms of the Budapest Treaty.

According to the second aspect process of this invention, the production of the antibiotic, caprazamycins may be carried out as described below.

Thus, the production of the antibiotic, caprazamycins is carried out by inoculating a microbial strain capable of producing at least one of the antibiotic caprazamycins A, B, C, E and E (this strain is referred hereinafter to simply as "a caprazamycin-producing strain") in a nutrient medium, and cultivating said microbial strain at an appropriate temperature to produce the antibiotic, a caprazamycin, whereby the culture containing the antibiotic caprazamycins is obtained. As the nutrient medium to be used for this purpose, there may be used any nutrient medium which is usable for the cultivation of actinomycetes. As the nutrient sources, there may be used nitrogen sources, for example, soybean flour, peptone, yeast extract, meat extract, corn steep liquor, ammonium sulfate and others which are commercially available. As carbon sources, there may be used carbohydrates such as tomato paste, glycerin, starch, glucose, galactose, dextrin and others, as well as fats and the like. Further, there may be used inorganic salts such as sodium chloride, calcium carbonate and the like, as additives. If necessary, other additives, for example, metal salts may be added in a very small amount. These additive substances may be any of those materials which are utilizable by a caprazamycin-producing strain and are useful for the production of the antibiotic caprazamycins,

and which are known to be utilizable in the culture media for the cultivation of actinomycetes.

For the production of the antibiotic caprazamycins, there may be used a microorganism which belongs to the genus Streptomyces and has an ability to produce the antibiotic caprazamycins. Specifically, the Streptomyces sp. MK730-62F2 as isolated by us has been confirmed to produce the antibiotic caprazamycins. Any other strain capable of producing said antibiotics is possible to be isolated from the nature by employing any known isolation technique which are available for the isolation of the antibiotic-producing strains. There still remains such possibility that the ability of a caprazamycin-producing strain, including Streptomyces sp. MK730-62F2, to produce the antibiotic caprazamycins is improved by subjecting such strain to a mutation treatment with radio-active radiation or others. Further, the antibiotic caprazamycins may be produced by a genetic engineering technique.

As a seed culture to be used for the production of caprazamycins, there may be used a growth which is obtained from a slant culture of the strain MK730-62F2 on an agar medium.

Upon the production of the antibiotic caprazamycins, it is preferable that a caprazamycin-producing strain belonging to the genus Streptomyces is cultivated in a suitable culture medium under aerobic conditions. The recovery of the desired caprazamycins(s) from the

resulting culture broth may be effected in a conventional manner. The cultivation temperature is not specifically limited, so far as it is within the range of temperatures at which the desired antibiotics can be produced without substantially preventing the growth of the caprazamycin-producing strain as used. The cultivation temperature may be chosen depending upon the nature of a caprazamycin-producing strain as used, and a preferred cultivation temperature is in a range of 25 to 30°C.

10       The production of caprazamycins by the strain MK730-62F2 can usually reach a maximum for 3 to 9 days of the cultivation of the strain. In general, however, the cultivation of the strain is continued until a sufficient antibacterial activity is given to the culture medium.

15       The time-dependent change in the potency of caprazamycins in the resulting culture broth may be measured either by HPLC method, or by a cylinder plate method in which Mycobacterium smegmatis or Mycobacterium vaccae is used as an assaying strain.

20       In the second aspect process of this invention, at least one of caprazamycins A, B, C, E and F is recovered from the culture broth which has been obtained as above. As the method for recovering and isolating the desired caprazamycin(s), there may appropriately be used any of

25       conventional methods which are used for the isolation of metabolite(s) as produced by microorganisms. For example, a method for extraction with an organic solvent immiscible with water, and a method for utilizing the difference in

the adsorption affinities of the caprazamicins onto various adsorbents, such as a synthetic adsorbent resin, silica gel and a method for gel filtration and chromatographic method with countercurrent distribution, etc. may be used, singly or in combination, in order to recover caprazamycin(s) A, B, C, E and/or F, either singly or in the form of a mixture of any two or more of them, from the culture broth supernatant. Further, from the microbial cells of the strain so separated from the culture broth, it is also possible to recover caprazamycin(s) A, B, C, E and/or F, by subjecting the microbial cells to a solvent extraction with a suitable organic solvent, or by a method comprising disrupting the cells and eluting the desired caprazamycin(s) out of the disrupted cells by extraction. Incidentally, the antibiotic caprazamycin(s) A, B, C, E and/or F may be harvested, separately or in combination. Incidentally, the isolation of caprazamycins A, B, C, E and F from each other may be effected by a high performance liquid chromatography (HPLC) with a suitable development solvent.

Further, according to a third aspect of this invention, there is provided a pharmaceutical composition which comprises as an active ingredient at least one of caprazamycins A, B, C, E and F having the general formula (I) or a salt thereof, in admixture with a pharmaceutically acceptable carrier or carriers.

The pharmaceutical composition according to the third aspect of this invention may be in the form of a

composition which comprises as the active ingredient a compound of the general formula (I), in admixture with a conventional, pharmaceutically acceptable solid or liquid carrier, for example, ethanol, water, physiological saline, starch and the like.

Caprazamycin(s) of the general formula (I) or a salt thereof, which is or are to be used in the pharmaceutical composition according to the third aspect of this invention, may be administered orally or parenterally by intravenous, intramuscular or intraperitoneal administration, and so on.

For the oral administrations, the pharmaceutical composition according to the third aspect of this invention may be formulated in the form of preparations such as powder, tablets, capsules, suspension, syrup and the like, by blending the active ingredient, namely a caprazamycin of general formula (I) or a salt thereof, with a conventional, pharmaceutically acceptable solid or liquid carrier.

The proportion of the compound of the general formula (I) which is incorporated as the active ingredient in the pharmaceutical composition of the third aspect of this invention may depend upon the type of the preparations, but a convenient proportion of a caprazamycin may be in the range of about 2 to 90 %, based on the weight of the dosage unit of the composition.

In cases where the composition of the third aspect of this invention is formulated into injections, a



preferred form of the injectionable preparations may include a sterilized aqueous solution or a sterilized and lyophilized preparation which contains the compound of the general formula (I) as active ingredient. As examples of  
5 the liquid carriers usable for this purpose, water, aqueous ethanol, glycerol, propylene glycol, vegetable oil and the like are preferred.

The dose of a caprazamycin of the general formula (I) or a salt thereof as an active ingredient in the  
10 composition of this invention may depend upon the nature of bacterial infections to be treated, a purpose of the therapeutic treatment, degree of the patient's conditions and so on. However, an optimal dose of a caprazamycin can be decided by experts through suitable preliminary tests.  
15 By the way, caprazamycin B did not exhibit any toxicity in mice (ICR type, 4 weeks-aged, male), when administered intravenously at a dose of 75 mg/kg.

According to a fourth aspect of this invention, there is further provided, as a novel microorganism,  
20 Streptomyces sp. MK730-62F2 which has a characteristic nature that it is capable of producing caprazamycins A, B, C, E and F of general formula (I) above, and which has been deposited in the "National Institute of Bioscience and Human-Technology, Agency of Industrial Science and  
25 Technology" as located at No. 1-3, Higashi 1-chome, Tsukuba-City, Ibaraki-Prefecture, Japan, under the deposit number "FERM BP-7218".

### Brief Description of Attached Drawings

Figure 1 is ultraviolet absorption spectrum of caprazamycin A in a methanolic solution.

Figure 2 is infrared absorption spectrum of caprazamycin A as measured by KBr-tableted method.

Figure 3 is proton nuclear magnetic resonance spectrum of caprazamycin A as measured in DMSO- $d_6$  solution at 500 MHz at room temperature.

Figure 4 is  $^{13}C$ -nuclear magnetic resonance spectrum of caprazamycin A as measured in DMSO- $d_6$  solution at 125 MHz at room temperature.

Figure 5 is ultraviolet absorption spectrum of caprazamycin B in a methanolic solution.

Figure 6 is infrared absorption spectrum of caprazamycin B as measured by KBr-tableted method.

Figure 7 is proton nuclear magnetic resonance spectrum of caprazamycin B as measured in a mixed solvent of DMSO- $d_6$ - $D_2O$  (10:1) at 500 MHz at room temperature.

Figure 8 is  $^{13}C$ -nuclear magnetic resonance spectrum of caprazamycin B as measured in a mixed solvent of DMSO- $d_6$ - $D_2O$  (10:1) at 125 MHz at room temperature.

Figure 9 is ultraviolet absorption spectrum of caprazamycin C in a methanolic solution.

Figure 10 is infrared absorption spectrum of caprazamycin C as measured by KBr-tableted method.

Figure 11 is proton nuclear magnetic resonance spectrum of caprazamycin C as measured in DMSO- $d_6$  solution at 500 MHz at room temperature.

206050-02664001

Figure 12 is  $^{13}\text{C}$ -nuclear magnetic resonance spectrum of caprazamycin C as measured in  $\text{DMSO-d}_6$  solution at 125 MHz at room temperature.

Figure 13 is ultraviolet absorption spectrum of caprazamycin E in a methanolic solution.

Figure 14 is infrared absorption spectrum of caprazamycin E as measured by KBr-tableted method.

Figure 15 is proton nuclear magnetic resonance spectrum of caprazamycin E as measured in  $\text{DMSO-d}_6$  solution at 500 MHz at room temperature.

Figure 16 is  $^{13}\text{C}$ -nuclear magnetic resonance spectrum of caprazamycin E as measured in  $\text{DMSO-d}_6$  solution at 125 MHz at room temperature.

Figure 17 is ultraviolet absorption spectrum of caprazamycin F in a methanolic solution.

Figure 18 is infrared absorption spectrum of caprazamycin F as measured by KBr-tableted method.

Figure 19 is proton nuclear magnetic resonance spectrum of caprazamycin F as measured in  $\text{DMSO-d}_6$  solution at 500 MHz at room temperature.

Figure 20 is  $^{13}\text{C}$ -nuclear magnetic resonance spectrum of caprazamycin F as measured in  $\text{DMSO-d}_6$  solution at 125 MHz at room temperature.

#### Best Mode for Carrying Out the Invention

This invention is now illustrated in more detail with reference to the following Examples.

#### Example 1

Production of the antibiotic caprazamycins A, B, C,

E and F

Streptomyces sp. MK730-62F2 (deposited under the depository number of FERM BP-7218), which had been cultured on agar slant culture medium, was inoculated in a culture medium. The culture medium used here had been prepared by placing into Erlenmeyer flasks (of 500 ml-capacity) 110 ml-portions of a liquid culture medium comprising 2 % galactose, 2 % dextrin, 1 % glycerine, 1 % Bacto-soyton (a product of Difco Co.), 0.5 % corn steep liquor, 0.2% ammonium sulfate, and 0.2 % calcium carbonate (adjusted a pH of 7.4) and sterilizing the culture medium in the flasks at 120°C for 20 minutes in a usual manner, before the inoculation of the strain MK730-62F2 was done. The liquid culture medium so inoculated was then subjected to shaking cultivation with rotation at 30°C for 2 days, thereby to afford a seed culture broth as intended.

In a tank fermenter (of 30 L-capacity), there was prepared 15 liters of a culture medium comprising 2.4 % tomato paste (a product of Kagome Co.), 2.4 % dextrin, 1.2 % yeast extract (a product of Oriental Co.) and 0.0006 % cobalt chloride (adjusted to a pH of 7.4), which was then sterilized so as to afford the productive culture medium. To this productive culture medium was inoculated a 2 % proportion of the above-mentioned seed culture broth. The cultivation of the strain MK730-62F2 was conducted in the tank fermenter under the conditions that the cultivation was effected for 6 days at a temperature of 27°C with aeration of 15 L of air per minute and agitation

at 200 rpm.

The resulting culture broth was centrifuged to separate into the culture broth filtrate (12 L) and the cultured microbial cells. Subsequently, methanol (6 L) was added to the microbial cells so separated, and the resultant mixture was well stirred to extract the caprazamycins from the cells into methanol. The culture broth filtrate as obtained and the methanolic extract of the cells (the methanol extract) were combined together, and the resulting mixture (18 L) was passed through a column comprising 750 ml of a synthetic adsorbent resin made of aromatic polymer, namely "Diaion HP-20" resin (a product of Mitsubishi Chemical Co., Japan), whereby the caprazamycins were adsorbed in the Diaion HP-20 resin. Through this Diaion HP-20 resin column containing the adsorbed caprazamycins, were passed a volume of deionized water, 50 % aqueous methanol (a mixture of 50 % methanol and 50% water), 80 % aqueous methanol(a mixture of 80 % methanol and 20% water), 80 % aqueous acetone (a mixture of 80 % acetone and 20% water) and acetone (each 2.25 L), in order. The caprazamycins have been eluted out mainly in the eluate fraction which was obtained by eluting with the 80 % aqueous acetone. In addition, the eluate fraction as eluted with the 50 % aqueous methanol and the eluate fraction as eluted with the 80 % aqueous methanol have contained caprazamycins, too. These two eluate fractions containing caprazamycins as eluted with the 50 % aqueous methanol and with the 80 % aqueous methanol were

combined together. The resulting mixture of these eluate fractions was again passed through a column of Diaion HP-20 resin (750 ml), whereby caprazamycins were adsorbed in the adsorbent resin of this column. Thereafter, 80 % aqueous methanol (2.25 L) was passed through this column. Then, elution was effected by passing 80 % aqueous acetone (2.25 L) through the column. The resulting eluate as eluted with the 80 % aqueous acetone at this time was then combined with the first-mentioned eluate fraction which had been obtained by eluting with the 80 % aqueous acetone at the earlier stage. The resulting mixture was concentrated to dryness under a reduced pressure, whereby a partially purified product comprising caprazamycins (10.1 g) was obtained.

15        This partially purified product comprising caprazamycins (10.1 g) was then dissolved in a mixed solvent (50ml) of chloroform-methanol (=1:2), and the resulting solution was added with Kieselgur (Art. 10601, a product of Merck & Co.,) (50 ml) and the solvent was

20        evaporated off to dryness under a reduced pressure. The resulting Kieselgur solids containing caprazamycins adsorbed therein was placed on the top of a silica gel column (54 mm inner diameter x 200 mm height) to be subjected to a chromatography. The development solvents

25        used for this chromatography purpose were solvent mixtures of chloroform-methanol-water (= 4:1:0.1); chloroform-methanol-water (= 2:1:0.2); and chloroform-methanol-water (= 1:1:0.2), and 1.35 L of the solvent mixture was used

for each time. The developing operations were carried out in order, with these solvent mixtures. The eluates from the silica gel column were collected each in fractions by means of a fraction collector, so that fractions Nos. 1 to 53 were collected each in 20 g-portions, and so that fractions Nos. 54 to 117 were collected each in 19 g-portions. In this way, the active fractions containing caprazamycins were eluted in fractions Nos. 66 to 83. These active fractions Nos. 66 to 83 were combined together and then concentrated to dryness under a reduced pressure, thus to afford a partially purified product comprising caprazamycins (625.3 mg).

Methanol (5 ml) was added to the partially purified product (625.3 mg) thus obtained. The resulting solution was allowed to stand at 5°C under cold and dark conditions, whereby a fraction of precipitate as deposited (537.3 mg) was obtained as a product which comprised caprazamycins.

Subsequently, the deposited precipitate (537.3 mg) comprising caprazamycins was purified by subjecting it to HPLC (CAPCELL PAK C18, diameter 20 mm x height 250 mm, a product of Shiseido Co., Japan). In this HPLC, the development was conducted with 50 % acetonitrile-water-0.05 % formic acid as the development solvent (at a flow rate of 12.0 ml/min.), whereby caprazamycin A was eluted after 61 to 68 minutes; caprazamycin B was eluted after 52 to 60 minutes; caprazamycin C was eluted after 39 to 41 minutes; caprazamycin E was eluted after 25 to 28 minutes; and caprazamycin F was eluted after 22 to 25 minutes of

the development. These active fractions were collected separately for each of the desired caprazamycins. Each of the separately collected active fractions was concentrated to dryness under a reduced pressure, to afford

5 caprazamycin A (56.9 mg), caprazamycin B (90.3 mg), caprazamycin C (19.7 mg), caprazamycin E (30.3 mg) and caprazamycin F (25.5 mg), respectively.

#### Industrial Applicability

As described hereinbefore, caprazamycins A, B, C, E  
10 and F having the general formula (I), which are provided as novel antibiotics according to this invention, each have excellent antibacterial activities against various acid-fast bacteria and various bacteria as well as their drug-resistant strains. Therefore, a caprazamycin  
15 according to this invention is effective and useful for treating bacterial infections as caused by acid-fast bacteria or bacteria.

20


25



## CLAIMS

1. An antibiotic, caprazamycin A, caprazamycin B, caprazamycin C, caprazamycin E or caprazamycin F, which is a compound represented by the following general formula

5 (I)




wherein R is tridecyl group for caprazamycin A; 11-methyl-dodecyl group for caprazamycin B; dodecyl group for caprazamycin C; undecyl group for caprazamycin E; and 9-methyl-decyl group for caprazamycin F, or a pharmaceutically acceptable salt thereof.

20


2. An antibiotic as claimed in Claim 1, which is caprazamycin A represented by the following formula (Ia)

25




that is, the compound of general formula (I) shown in Claim 1 where R is tridecyl group  $-(CH_2)_{12}-CH_3$ .


3. An antibiotic as claimed in Claim 1, which is caprazamycin B represented by the following formula (Ib)



that is, the compound of general formula (I) shown in Claim 1 where R is 11-methyl-dodecyl group




4. An antibiotic as claimed in Claim 1, which is  
5 caprazamycin C represented by the following formula (Ic)




that is, the compound of general formula (I) shown in  
Claim 1 where R is dodecyl group  $\text{---}(\text{CH}_2)_{11}\text{---CH}_3$ .

5. An antibiotic as claimed in Claim 1, which is  
20 caprazamycin E represented by the following formula (Ie)




that is, the compound of general formula (I) shown in Claim 1 where R is undecyl group  $-(CH_2)_{10}-CH_3$ .

6. An antibiotic as claimed in Claim 1, which is caprazamycin F represented by the following formula (If)



that is, the compound of general formula (I) shown in Claim 1 where R is 9-methyl-decyl group



7. A process for the production of an antibiotic,  
 5 caprazamycin A, caprazamycin B, caprazamycin C,  
 caprazamycin E and/or caprazamycin F represented by the  
 general formula (I) given in Claim 1, characterized in  
 that the process comprises culturing a microbial strain  
 which belongs to the genus Streptomyces and which is  
 10 capable of producing at least one of caprazamycin A,  
 caprazamycin B, caprazamycin C, caprazamycin E and  
 caprazamycin F, and recovering at least one of  
 caprazamycins A, B, C, E and F from the resulting culture.

8. A process as claimed in Claim 7, wherein as  
 15 the microbial strain capable of producing at least one of  
 caprazamycins A, B, C, E and F, there is used Streptomyces  
 sp. MK730-62F2 which has been deposited in the National  
 Institute of Bioscience and Human-Technology, Agency of  
 Industrial Science and Technology, under the deposit  
 20 number of "FERM BP-7218" in terms of the Budapest Treaty.

9. A pharmaceutical composition comprising as an  
 active ingredient at least one of caprazamycins A, B, C, E  
 and F having the general formula (I) given in Claim 1, or  
 a salt thereof, in admixture with a pharmaceutically  
 25 acceptable carrier or carriers.

10. A composition as claimed in Claim 9, which is  
 an antibacterial composition.

11. As a novel microorganism, Streptomyces sp.

206050-02664001

MK730-62F2 which has a characteristic nature that it is capable of producing caprazamycins A, B, C, E and F having the general formula (I) given in Claim 1, and which has been deposited in the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, under the deposit number of "FERM BP-7218".


10

15

20

25

There have been obtained, by cultivation of Streptomyces sp. MK730-62F2 (deposit number of FERM BP-7218), antibiotic caprazamycins A to F having by the following general formula (I)



wherein R is tridecyl group, 11-methyl-dodecyl group, and others. These caprazamycins have excellent antibacterial activities against various acid-fast bacteria and various bacteria as well as their drug-resistant strains.

FIG. 1






FIG. 2




FIG. 3





FIG. 4



206050-02664001

FIG. 5




FIG. 6




FIG. 7





FIG. 8



206050-066400F


**FIG. 9**



FIG. 10




FIG. 11





FIG. 12



205050\*0466400F

FIG. 13




FIG. 14




FIG. 15






FIG. 16



206050\*02554007


FIG. 17



206050\*0466400F




FIG. 18




206050\* 04664001

FIG. 19



206050\*066400F

FIG. 20





## UNITED STATES

PATENT APPLICATION  
DECLARATION AND POWER OF ATTORNEY - ORIGINAL APPLICATION

ATTORNEY'S DOCKET NO.

205,511

As a below named Inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name:

I verily believe I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named below) of the invention entitled

(1) ANTIBIOTIC CAPRAZAMYCINS AND PROCESS FOR PRODUCING THE SAME  
the specification of which(2) ☐ is attached hereto.☒ was filed on 11 August 2000 as Application No. PCT/JP00/05415  
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application under 37 CFR 1.56(a); the invention has not been patented or made the subject of a inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to this application; and as to applications for patents or inventor's certificate on the invention filed in any country foreign to the United States prior to this application by me or my legal representatives or assigns,

(3) ☐ no such applications have been filed, or☒ such applications have been filed as follows:

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED WITHIN 12 MONTHS PRIOR TO THIS APPLICATION				
Country	Application Number	Date of Filing (day, month, year)	Date of Issue (day, month, year)	Priority Claimed Under 35 USC 119
(4)				<input type="checkbox"/> Yes <input type="checkbox"/> No
				<input type="checkbox"/> Yes <input type="checkbox"/> No
ALL FOREIGN APPLICATIONS, IF ANY, FILED MORE THAN 12 MONTHS PRIOR TO THIS APPLICATION				
(4) Japan	11-228866	12 August 1999		x Yes

I hereby claim the benefit under Title 35, United States Code § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

(5) COMPLETE  
DATA INDICATED  
IF APPLICABLE

(5) (Application Ser. No.) (Filing date) (Status: patented, pending, abandoned)

(5) (Application Ser. No.) (Filing date) (Status: patented, pending, abandoned)



Power of Attorney: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Jeffrey A. Schwab, Registration Number 24,490  
Stewart J. Fried, Registration Number 20,694  
Jay S. Cinamon, Registration Number 24,156

Dennis A. Mason, Registration Number 19,571  
Michael I. Markowitz, Registration Number 30,659  
Thomas E. Spath, Registration Number 25,928

Send Correspondence To:  
Abelman, Frayne & Schwab  
150 East 42nd Street  
New York, New York 10017-5612

Direct Telephone Calls To:  
Jeffrey A. Schwab, Stewart J. Fried  
Jay S. Cinamon, Dennis A. Mason,  
Michael I. Markowitz or  
Thomas E. Spath at (212) 949-9022

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(6) DETAILS  
REQUIRED  
FOR EACH  
INVENTOR

Full Name of Sole or First Inventor <u>Tomio TAKEUCHI</u>	Inventor's Signature <u>Tomio Takeuchi</u>	Date 09 Feb. 2002
Residence New Fuji Mansion 701, 1-11, Higashi Gotanda 5-chome, Shinagawa-ku, Tokyo, Japan JPX	Citizenship Japanese	
Post Office Address Same as above		
Full Name of Second Joint Inventor, If Any <u>Masayuki IGARASHI</u>	Inventor's Signature <u>Masayuki Igarashi</u>	Date 09 Feb. 2002
Residence Atsugi Green Copo 802, 10-4, Nakacho 4-chome, Atsugi-shi, Kanagawa, Japan JPX	Citizenship Japanese	
Post Office Address Same as above		
Full Name of Third Joint Inventor, If Any <u>Hiroshi NAGANAWA</u>	Inventor's Signature <u>Hiroshi Naganawa</u>	Date 09 Feb. 2002
Residence 3-17, Denenchofu Honcho, Ohta-ku, Tokyo, Japan JPX	Citizenship Japanese	
Post Office Address Same as above		
Full Name of Fourth Joint Inventor, If Any <u>Masa HAMADA</u>	Inventor's Signature <u>Masa Hamada</u>	Date 09 Feb. 2002
Residence 17-2, Honshiocho, Shinjuku-ku, Tokyo, Japan JPX	Citizenship Japanese	
Post Office Address Same as above		
Full Name of Fifth Joint Inventor, If Any	Inventor's Signature	Date
Residence	Citizenship	
Post Office Address		
Full Name of Sixth Joint Inventor, If Any	Inventor's Signature	Date
Residence	Citizenship	
Post Office Address		